An HIV-derived nucleoside therapy now treats rare genetic diseases by restoring mitochondrial DNA and improving muscle ...

Clin Drug Invest. 2007;27(8):509-531. Because of its poor tolerability, regimen complexity and drug-interaction potential relative to other new NRTIs, use of didanosine has decreased over the last few ...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified as the causative agent of the COVID-19 (coronavirus disease 2019) pandemic, was first detected in Wuhan, China late December ...

De novo and acquired drug resistance limit the effectiveness of nucleoside analogue chemotherapy, and the responsible molecular mechanisms are under intense study. Lack of intracellular drug ...

The coronavirus disease 2019 (COVID-19) pandemic has infected around 225 million people and claimed more than 4.64 million lives worldwide. This pandemic is caused by severe acute respiratory syndrome ...

Obeldesivir (GS-5245), a novel investigational small molecule oral antiviral, represents a new tool in the ongoing effort to prepare for future pandemics. Obeldesivir (GS-5245), a novel ...

In July 2000, a 58-year-old man infected with the human immunodeficiency virus (HIV) began treatment with highly active antiretroviral therapy, which initially consisted of zidovudine, lamivudine, and ...

Antiviral nucleoside analogues represent a pivotal class of compounds that mimic physiological nucleosides and are enzymatically incorporated into viral genomes, thereby inhibiting viral polymerases ...

Scientists have modeled all of the steps by which nucleosides and their analogs are transported into cells by a specific molecule named the concentrative nucleoside transporter or CNT. The finding ...

Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...